Navigation Links
USF and Saneron get $2.6 million to develop Alzheimer's treatment using umbilical cord blood cells
Date:10/5/2010

The National Institutes of Health has awarded a three-year, $2.6-million grant to the University of South Florida and Tampa-based biotechnology company Saneron-CCEL Therapeutics, Inc., to establish dosing and safety guidelines for transplanting human umbilical cord blood cells (HUBC) into animal models of Alzheimer's disease. The researchers hope to use the pre-clinical data to gain U.S. Food and Drug Administration approval to carry out clinical trials with patients suffering from Alzheimer's disease.

"Our immediate goal is to move our beneficial findings with cord blood cells into clinical trials for patients with mild to moderate Alzheimer's disease," said the grant's principal investigator Dr. Jun Tan, a USF neuroscientist and professor of psychiatry.

The NIH Phase II Small Business Technology Transfer grant is based on the success of an ongoing research partnership between USF and Saneron aimed at determining the therapeutic benefits HUBCs offer when transplanted into animal models of a variety of neurological diseases, including Parkinson's disease, Lou Gehrig's disease (ALS), Alzheimer's disease and stroke.

"Our next stage of research is translational. This study's primary aims are the completion of preclinical safety and validation studies and the submission of an Investigational New Drug application to the FDA for a Phase I clinical trial," said Nicole Kuzmin-Nichols, president and chief operating officer of Saneron. "Saneron is very pleased and excited that our long-standing research partnership with USF has provided this opportunity to further the commercialization of technology that was developed at USF and transferred to Saneron for further development."

Additional funding will be provided by a Florida High Tech Corridor Industry Matching Grant through USF Connect.

Previous research by USF and Saneron has shown that injecting HUBC into laboratory (in vitro) and animal models (in vivo) of neurodegenerative diseases does not promote a strong immune response, so rejection is not a problem, Dr. Tan said. The potential for HUBCs to promote an anti-inflammatory response may provide overall benefits. Inflammation is a biochemical component of Alzheimer's disease.

Saneron CCEL Therapeutics, Inc. worked with USF to develop a HUBC cell technology platform called the U-CORD-CELL program. The program aims to improve the quality of life for patients by developing and producing innovative, high-quality treatments for neurological and cardiac diseases.

"This grant will afford Saneron the opportunity to bring the U-CORD-CELL technology to the clinic in the pursuit of a potential therapy for those suffering from Alzheimer's disease," Kuzmin-Nichols said.

According to USF senior vice president for research and innovation, Karen Holbrook, PhD, this collaborative work between USF and Saneron is the "essence of technology transfer."

"The best outcome for this kind of collaboration is when technology developed at the university is taken to the patient's bedside," said Dr. Holbrook. "USF is happy and proud to be working with Saneron on this most important research."


'/>"/>

Contact: Randolph Fillmore
rfillmor@health.usf.edu
813-974-0868
University of South Florida (USF Health)
Source:Eurekalert

Related medicine news :

1. Amway One by One Campaign for Children Reaches 7 Million Kids
2. Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinsons Drug Development
3. International Diabetes Federation awards $2 million to 9 global diabetes research projects
4. New Report: $1 Cigarette Tax Increase Would Raise $418.8 Million for Texas and Cut Youth Smoking
5. New Report: $1 Cigarette Tax Increase Would Raise $18.6 Million for Montana and Cut Youth Smoking
6. New Report: $1 Cigarette Tax Increase Would Raise $24.8 Million for Wyoming and Cut Youth Smoking
7. New Report: $1 Cigarette Tax Increase Would Raise $43.3 Million for Utah and Cut Youth Smoking
8. New Report: $1 Cigarette Tax Increase Would Raise $113.9 Million for Colorado and Cut Youth Smoking
9. New Report: $1 Cigarette Tax Increase Would Raise $65.3 Million for Iowa and Cut Youth Smoking
10. Kaiser Permanente Approves $170 Million in Community Benefit Grants in 2009
11. America's Hidden Pandemic: 100 Million Suffer From Sleep Problems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... Diego, CA (PRWEB) , ... May 25, 2016 , ... There was a time when ... women are going with the flow and turning to menstrual cups, like Lunette . ... party, Lunette is introducing their new anthem in this catchy video ! , ...
(Date:5/25/2016)... ... May 25, 2016 , ... New studies published ... injured workers across 15 states. The outcomes examined in these studies include recovery ... care, and satisfaction with medical care. , “The goal of the studies is ...
(Date:5/25/2016)... ... May 25, 2016 , ... The ... Drug Development through Molecular Imaging.” The focus of ADDMI-IG will be geared towards ... and development pipeline issues. Through ADDMI-IG WMIS will provide a platform for productive ...
(Date:5/25/2016)... , ... May 25, 2016 , ... ... to industries ranging from medical and pharmaceutical, to food and HVAC facilities. Their ... as on-site training. , For medical applications, Afrimesure offers a variety of ...
(Date:5/25/2016)... ... May 25, 2016 , ... The University of San Francisco (USF) has named ... lead a team of more than 100 full-time faculty and staff, and serve as ... in late August. , Baker comes to USF from the University of Washington in ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , May 25, 2016 Digital Health ... to it by the US Patent and Trademark ... technology includes proprietary processes for electronic opt-­in and ... and wellness programs, HIPAA compliance and otherwise. ... "Our technology allows for ...
(Date:5/25/2016)... 2016 ReportsnReports.com adds "Chronic ... that provides an overview on therapeutic pipeline of ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Chronic Cough ...
(Date:5/24/2016)... , May 24, 2016 ... beide primären Endpunkte und ... Überlegenheit in ‚ausgezeichneter plus guter ... Colons    ,      (Logo: ... gab heute neue positive Daten von der MORA-Studie ...
Breaking Medicine Technology: